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Introduction
Apoptosis is a physiological form of cell death characterized
by nuclear chromatin condensation, cytoplasmic shrinking and
membrane blebbing (Lauber et al., 2004; Schmitz et al., 2000).
This form of programmed cell death is predominantly induced
by cancer therapy (Kawanishi and Hiraku, 2004; Wesselborg
and Lauber, 2005). The two best-studied cell death signalling
pathways include the extrinsic/cell death receptor pathway and
the intrinsic/mitochondrial-initiated pathway (Greil et al.,
2003; Los et al., 1999). The death receptor family [the tumor
necrosis factor receptor (TNF-R) superfamily] includes CD95
(Fas/APO-1), TNF-R1, DR3, DR4 (TRAIL-R1) and DR5
(TRAIL-R2) receptors. Upon ligation, these receptors recruit
the FADD-adapter protein and the apical caspase-8 (or
caspase-10), resulting in the formation of the death-inducing
signalling complex (DISC). Following this, caspase-8 is
activated and released from the DISC, and further acts on
downstream effector molecules (Los et al., 1999; Sartorius et
al., 2001). The mitochondrial death pathway is activated in the
presence of diverse apoptotic stimuli, such as anti-cancer
drugs, UV and -irradiation (Hill et al., 2003). The tumor
suppressor gene p53 and the orphan steroid receptor Nur77
have been proposed as being the main molecules capable of
transmitting the apoptotic signal from the nucleus to the
mitochondria (Erster and Moll, 2004; Jeong et al., 2003; Lane
and Hupp, 2003; Li et al., 2000). The initial common event
during activation of the intrinsic/mitochondrial death pathway
is the release of cytochrome c. Cytochrome c triggers the
formation of a multimeric Apaf-1/cytochrome c/dATP/pro-
caspase-9 protein complex called the apoptosome, and leads to
the activation of caspase-9. Caspase-9 then cleaves and
activates downstream caspases, including caspase-3, caspase-
6 and caspase-7. This pathway is regulated at several levels.
The mitochondrial apoptotic pathway is negatively modulated
by the anti-apoptotic Bcl-2 family members, which block the
release of cytochrome c from the mitochondria. Furthermore,
caspase activation and the activity of already active caspases
can be inhibited by the ‘inhibitor of apoptosis proteins’ (IAPs).
In turn, IAPs can be inactivated by Smac/DIABLO or
OMI/HtrA2, two regulatory proteins that are released from
mitochondria.
Several strategies have been pursued to develop cancer
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Apoptin, a small proline-rich protein derived from the
chicken anaemia virus, induces cell death selectively in
cancer cells. The signalling pathways of apoptin-induced,
cancer cell-selective apoptosis are not well understood.
Here, we demonstrate that apoptin triggers apoptosis by
activating the mitochondrial/intrinsic pathway, and that it
acts independently of the death receptor/extrinsic pathway.
Jurkat cells deficient in either FADD or caspase-8 (which
are both necessary for the extrinsic pathway) were equally
as sensitive to apoptin as their parental clones. This
demonstrates that apoptin is likely to act through the
mitochondrial death pathway. Apoptin treatment causes a
loss of mitochondrial membrane potential, and release of
the mitochondrial proteins cytochrome c and apoptosis-
inducing factor. Apoptin-induced cell death is counteracted
by the anti-apoptotic Bcl-2 family members, Bcl-2 itself and
Bcl-XL, as shown in Jurkat leukaemia cells. In addition, we
describe the processing and activation of caspase-3. By
contrast, cleavage of caspase-8, which is predominantly
triggered by the death receptor pathway, is not observed.
Furthermore, apoptin triggers the cytoplasmic
translocation of Nur77, and the inhibition of Nur77
expression by siRNA significantly protects MCF7 cells
from apoptin-triggered cell death. Thus, our data indicate
that the apoptin death signal(s) ultimately converges at the
mitochondria, and that it acts independently of the death
receptor pathway.
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selective therapies. The most broadly applied approaches
explore defects in the regulation of the cell cycle (cell cycle
check-points), which are commonly found in cancer cells
(Blagosklonny and Darzynkiewicz, 2005; Westwell, 2004).
Other strategies for selective cancer therapy involve molecules
that act on and kill cancer cells preferentially, leaving normal
cells unaffected. Several viruses require (rapidly) dividing cells
for the completion of their lifecycle, thus viral proteins have
gained attention as potential cancer selective therapeutics
(Cassens et al., 2003; Cornelis et al., 2004; Oro and Jans,
2004).
Apoptin is a viral protein that fulfils these expectations.
Derived from the chicken anaemia virus (CAV), this 14 kDa
protein selectively induces apoptosis in a wide variety of
transformed cells but not in primary cells (Danen-Van
Oorschot et al., 1997; Oro and Jans, 2004; Poon et al., 2005).
However, the transient acquisition of a transformed-like
phenotype (for example, by the regulated expression of the
SV40 large T antigen, or by irradiation with ultraviolet-B)
renders even primary cells sensitive to apoptin (Oro and Jans,
2004; Zhang et al., 2004). The cancer-selective toxicity of
apoptin correlates with its cellular localization. Apoptin
enters the nuclei of cancerous cells, whereas in non-
transformed cells it remains in the cytoplasm (Guelen et al.,
2004). However, the forced targeting of apoptin into the
nuclei of primary cells is not sufficient for apoptin’s toxicity.
The current hypothesis is that nuclear trafficking and tumor-
specific phosphorylation of apoptin at Thr-108 are essential
for the induction of apoptosis (Guelen et al., 2004; Rohn et
al., 2002). Recently, Rohn and colleagues reported that
phosphorylation of apoptin is required for apoptosis, but that
abolishing the phosphorylation site of apoptin does not
significantly disrupt its nuclear input into tumor cells (Rohn
et al., 2005).
The signalling pathways involved in apoptin-induced cell
death are not well understood. It has been reported that
apoptin-induced cell death is independent of the p53 status of
the cell. Recently, it has also been shown that apoptin
associates with the anaphase-promoting complex and induces
G2/M arrest and apoptosis (Teodoro et al., 2004). It has also
been shown that apoptin co-localizes with Bcl-10 and FADD
(Guelen et al., 2004). Both Bcl-10 and FADD form death
effector filaments in the cytoplasm when overexpressed;
however, the functional significance of the interaction of
apoptin with these proteins still remains to be established.
By using cells with defective FADD or caspase-8 (key
players in death receptor signalling) and other molecular tools,
we demonstrate that apoptin acts independently of death
receptor signalling. Instead, apoptin triggers the activation of
the mitochondrial death pathway. In addition, we demonstrate
an apoptin-triggered release of cytochrome c and apoptosis-
inducing factor (AIF) from mitochondria that can be
counteracted by anti-apoptotic Bcl-2 family members. Nur77
translocates to the cytoplasm upon apoptin-triggered cell death,
and the inhibition of Nur77 expression by siRNA significantly
protects cells against apoptin-triggered cell death.
Materials and Methods
Cell culture and reagents
Jurkat (T-cell leukaemia) cells, Jurkat clones stably transfected with
FADD-DN (a dominant-negative FADD mutant lacking the N-
terminal DED), caspase-8 deficient Jurkat cells, BJAB (B-cell
lymphoma) cells, a BJAB clone expressing FADD-DN, PC-3 (prostate
cancer) cells, and MCF7, MCF7-caspase-3 and MCF7-Bcl-2 (breast
adenocarcinoma) cells were grown in RPMI-1640 medium
supplemented with 10% fetal calf serum (Hyclone), 100 g/ml
penicillin and 0.1 g/ml streptomycin (Gibco BRL). The cells were
grown at 37°C with 5% CO2 in a humidified incubator. The peripheral
blood mononuclear cells were isolated by Ficoll-gradient
fractionation, as described previously (Los et al., 1995). The following
antibodies were used: murine anti-cytochrome c, anti-AIF, rabbit anti-
Nur77, anti-haemagglutinin tag (anti-HA, Biomeda), anti-tubulin
(Santa Cruz Biotechnologies), rabbit anti-caspase-3, mouse anti-
caspase-8, anti-CD95 IgM (Upstate Cell Signaling) and anti-CD95
neutralizing (anti-APO-1) IgG1 (a kind gift from Dr H. Walczak,
DKFZ, Heidelberg, Germany).
Purification of TAT-apoptin and TAT-GFP
Plasmids expressing TAT-apoptin and TAT-GFP were a kind gift
from Dr Tavassoli (King’s College, London, UK). The recombinant
plasmids were expressed in a bacterial system, and then purified by
nickel-chromatography as described previously (Guelen et al., 2004).
Cell fractionation
Cytoplasmic, nuclear and mitochondrial fractions were separated by
differential centrifugation (Wu et al., 2002). Briefly, the cells were
treated with apoptin, then harvested and washed once with PBS after
the indicated time points. The cells were re-suspended for 5 minutes
on ice in a lysis buffer: 10 mM Tris-HCl (pH 7.8), 1% Nonidet P-40,
10 mM -mercaptoethanol, 0.5 mM PMSF, 1 mg/ml aprotinin and 1
mg/ml leupeptin. In some experiments, an equal amount of distilled
water was added to the cells in order to increase the cell lysis. Cells
were then sheared by passing them through a 22-gauge needle. The
nuclear fraction was recovered by centrifugation at 600 g for 5
minutes, and the ‘low-speed’ supernatant was centrifuged at 10,000 g
for 30 minutes to obtain the mitochondrial fraction (pellet) and the
cytosolic fraction (supernatant). The mitochondrial fraction was
further lysed in the buffer: 10 mM Tris (pH 7.4), 150 mM NaCl, 1%
Triton X-100, 5 mM EDTA (pH 8.0).
Measurement of mitochondrial membrane potential
Mitochondrial permeability transition was determined by staining the
cells with 5,5,6,6-tetrachloro-1,1,3,3-tetraethyl-benzimidazolyl
carbocyanine iodide (JC-1; Molecular Probes), as described
previously (Bedner et al., 1999). The mitochondrial membrane
potential was quantified by flow cytometric determination of cells
with a decreased fluorescence in the FL-2 channel. Data were
collected and analysed using a FACSCalibur (Becton Dickinson)
equipped with CELLQuest software. Data were given in percent cells
with low m, which reflects the percentage of cells losing the
mitochondrial membrane potential.
Immunoblotting
The release of cytochrome c and AIF from mitochondria, and the
cleavage of caspase-3, were detected by immunoblotting. The cells
were treated with apoptin for the indicated time periods and the
extracts were prepared as described above. Protein (30 g) was
separated by denaturing SDS-PAGE and then transferred onto nylon
membranes. The membranes were blocked in 5% non-fat dried milk
in TBS and then incubated overnight with the primary antibodies at
4°C. Then, the blots were incubated with the corresponding secondary
antibodies conjugated with HRP at room temperature for 1 hour.
Visualization was carried out by enhanced chemiluminescence (ECL)
detection (Amersham-Pharmacia Biotech).
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Measurement of apoptosis by flow cytometry
Apoptosis was measured by using the Nicoletti method (Barczyk et
al., 2005). Briefly, cells grown in suspension were treated with
purified TAT-apoptin (1 M) or TAT-GFP (control) for the indicated
time periods, and then harvested by centrifugation at 800 g for 5
minutes. The cells were washed once with PBS, and then re-
suspended in a hypotonic PI lysis buffer (1% sodium citrate, 0.1%
Triton X-100, 0.5 mg/ml RNase A, 40 g/ml propidium iodide). Cell
nuclei were then incubated for 30 minutes at 30°C and the nuclei were
subsequently analyzed by flow cytometry. Nuclei to the left of the G1
peak containing hypodiploid DNA were considered to be apoptotic.
MTT-assay
The MTT-assay was performed exactly as described previously
(Ghavami et al., 2005). Briefly, the experiment was performed in a
96-well (flat-bottomed) plate. Towards the end of the experiment, 10
l of 5 mg/ml tetrazolium salt [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrasolium bromide (MTT)] dissolved in PBS was added to
the cells in 100 l of medium. Cells were then incubated for 4 hours
at 37°C. At the end of the incubation time, the cells were spun down
to the bottom of the 96-well-plate at 90 g for 10 minutes, and the
supernatant was discharged by rapid inverting of the plate. 150 l of
ethanol:DMSO mix (1:1) was added per well and then the plate was
placed on a shaker for 20 minutes to solubilize the formazan crystals.
Absorbance was measured using a spectrophotometer equipped with
=570 nm (measurement) and =630 nm (reference) filters.
Immunocytochemistry and confocal imaging
Cells were grown overnight on coverslips and then transfected with
GFP-apoptin. After 36 hours, the cells were washed with PBS and
then fixed in 4% paraformaldehyde. Then, the cells were
permeabilized with 0.1% Triton X-100. To detect AIF release, the
cells were incubated with anti-AIF mouse IgG (Santa Cruz
Biotechnology; diluted 1:500). Following three wash steps with PBS,
the AIF-antibody complexes were stained with the corresponding
Cy3-conjugated secondary antibody (diluted 1:2500), then washed
twice with PBS. To visualize nuclei, cells were stained with DAPI (10
g/ml). The mitochondria were stained with Mitotracker Red
CMXRos (Molecular Probes; 200 nM in RPMI medium for 15
minutes, prior to fixing), a mitochondrial specific dye. The fluorescent
images were then observed and analyzed using an Olympus-IX81, a
multi-laser confocal microscope.
RNA intereference (RNAi)
The target siRNA for Nur77 (CAG UCC AGC CAU GCU CCU) and
the scrambled siRNA were purchased from Dharmacon RNA
technologies. The cells were grown to 90% confluency and then
transfected with the siRNA duplex (100 nM final concentration)
using Lipofectamine (Invitrogen) according to the manufacturer’s
instructions. The expression of the Nur77 was determined by
immunoblotting at 0, 12, 24 and 30 hours post-transfection.
Results
Apoptin-induced cell death is independent of the death
receptor pathway
To delineate the apoptin-triggered death pathways, we used
recombinant TAT-apoptin, which can enter cells as a result of
the attached TAT-transport peptide (Guelen et al., 2004). TAT-
apoptin accumulated within the nuclei of transformed cells,
whereas the TAT-GFP used as a control was evenly distributed
within the cell (Fig. 1A). The nuclear accumulation of TAT-
apoptin was not restricted to the recombinant protein itself, as
transiently expressed apoptin also accumulated in the nucleus
of transformed cells (data not shown). The peripheral blood
mononuclear (primary) cells were fully resistant to TAT-
apoptin (Fig. 1B). The addition of IL-2 (5 U) to some samples
to prevent spontaneous cell death had a much stronger impact
on cell viability than did the apoptin itself. By contrast, Jurkat
T-cell leukaemia cells were highly sensitive to TAT-apoptin
treatment (Fig. 1C,D, Fig. 3B). The resistance to apoptin
observed in primary cells was due to the difference between its
cellular distribution in the primary cells and in the Jurkat T-
cell leukaemia cells. Whereas in primary cells TAT-apoptin was
localized mainly in the cytoplasm, in Jurkat cells it was found
in the nucleus (Fig. 1F). Thus, the data confirm earlier
observations indicating that apoptin is selectively toxic for
transformed cells (Danen-Van Oorschot et al., 1997; Oro and
Jans, 2004; Teodoro et al., 2004; Poon et al., 2005).
Next, we tested the role of components of the death receptor
signal transduction pathway in apoptin-induced cell death.
FADD and caspase-8 are the key downstream signalling
components of the death-inducing signalling complex (DISC),
a multi-protein structure formed upon ligation of the death
receptors of the TNFR/NGFR family, which initiate apoptotic
signalling through the death receptor pathway. To delineate the
role of the DISC-components in apoptin-triggered death, we
used Jurkat T cells that lacked the expression of caspase-8
[Jurkat-Caspase-8(–/–)]. The caspase-8-deficient Jurkat cells
were as sensitive to TAT-apoptin-induced apoptosis as the
wild-type Jurkat cells were (Fig. 1C). Next, we tested the
role of the FADD adaptor molecule in the apoptin-triggered
death pathway, by using Jurkat cells overexpressing a
truncated, dominant-negative form of FADD (FADD-DN).
Overexpression of FADD-DN prevents the formation of a
functional DISC, and thus the activation of caspase-8 that is
triggered not only by CD95-L/Fas-L, but also by TRAIL or
anti-APO-1-antibodies (Sprick et al., 2000; Stroh et al., 2002).
The cells were treated with TAT-apoptin and, after the indicated
time points, apoptosis was measured by flow cytometry. After
48 hours of apoptin treatment, about 55% of both the parental
Jurkat cells and the cell clones overexpressing FADD-DN were
killed. Thus, the state of FADD has no effect on the cell death
induced by apoptin in Jurkat cells (Fig. 1D). The same pattern
is observed with the cells treated for 72 and 96 hours,
respectively. In a control experiment, Jurkat cells lacking
FADD or caspase-8 activity, and the ‘wild type’ cells were
treated with an agonistic anti-CD95 antibody that crosslinks
the CD95/APO-1/Fas receptor molecule and induces cell death
through a caspase-8/FADD-dependent mechanism. After 8
hours of treatment with the anti-CD95 antibody, wild-type cells
showed an increased amount of cell death, whereas the cells
either lacking caspase-8 or overexpressing FADD-DN were
completely resistant (Fig. 1E). These results suggest that cell
death induced by apoptin does not depend on caspase-8 or
FADD. To confirm the data generated using Jurkat cells, we
also verified the cell death induced by apoptin in a human B
cell line, BJAB, stably expressing FADD-DN (Chinnaiyan et
al., 1995). Measurement of the cell death induced by apoptin
showed no difference in mutant cell lines when compared with
that of the wild-type cells (data not shown).
In order to further confirm the above findings, we inhibited
the activation of CD95 by using a neutralizing anti-APO-1
(IgG1) antibody. Unlike the anti-APO-1 IgG3 and anti-CD95
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IgM antibodies that can exist as polymers and can thus activate
CD95/Fas/APO-1, anti-APO-1 IgG1 exists only in the
monomeric form and thus it fails to induce the CD95
trimerization that is required for activation of the CD95-death
pathway. The anti-APO-1 IgG1 antibody strongly reduced the
cell death induced by the stimulatory anti-CD95 (IgM)
antibody. By contrast, apoptosis induced by apoptin was not
affected by the neutralizing anti-CD95 antibody (Fig. 2A,B).
Thus, all of the above data indicate that apoptin acts
independently of the death receptor signalling pathway.
Mitochondrial membrane potential is lost during apoptin-
induced cell death, and anti-apoptotic Bcl-2 family
members block apoptin-induced apoptosis
To gain more insight into the mechanism of apoptotic
signalling triggered by apoptin, we investigated the
mitochondrial/apoptosome-dependent apoptotic pathway. The
mitochondrial pathway is mainly triggered by cell death signals
that cause cellular stress. These signals frequently cause the
loss of the mitochondrial membrane potential (M). Thus,
we studied the effect of apoptin on the mitochondrial
membrane potential. The M was monitored by JC-1, a
mitochondrial dye that shows decreased fluorescence when the
mitochondrial membrane potential is lost. Cells treated with
apoptin showed a significant loss of mitochondrial membrane
potential when compared with the untreated cells (Fig. 3A).
Furthermore, deficiency of either caspase-8 or FADD had no
effect on the loss of mitochondrial membrane potential caused
by apoptin. This experiment indicates that apoptin-triggered
cell death is associated with the loss of mitochondrial
membrane potential, and it further suggests that apoptin kills
the cells independently of the death receptor pathway.
The intrinsic/mitochondrial cell death pathway is
negatively modulated by the anti-apoptotic Bcl-2 family
members. We therefore tested whether overexpression of Bcl-
2 or Bcl-XL, affects the apoptin-triggered death pathway. As
shown in Fig. 3B, both Bcl-2 and Bcl-XL strongly inhibited
apoptin-induced cell death, whereas about 80% of the
parental Jurkat cells were killed by apoptin. To broaden the
above conclusion, we tested the effect of apoptin on MCF7
human breast adenocarcinoma cells, which do not express
caspase-3, as well as on a clone of MCF7 cells re-transfected
with caspase-3 and MCF7 cells overexpressing Bcl-2. MCF7
cells showed significant sensitivity to TAT-apoptin, which
was augmented by the expression of caspase-3 but
significantly inhibited by Bcl-2 (Fig. 3C). Thus, these data
confirm our previous observations, indicating that the
mitochondrial death pathway is triggered by apoptin, as well
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Fig. 1. Apoptin-induced cell death is independent of FADD and
caspase-8. (A) MCF7 and PC-3 cells treated with recombinant TAT-
GFP (1 M) or with recombinant TAT-apoptin (1 M), and counter-
stained with DAPI. TAT-GFP localizes both to the nucleus and to the
cytoplasm, whereas TAT-apoptin is found almost exclusively in the
nuclei (arrows). TAT-apoptin was detected using an anti-
haemagglutinin-tag antibody; the tag is incorporated between TAT
and the apoptin itself within the fusion protein. Cells treated with
TAT-GFP show normal morphology, whereas some of the cells
treated with TAT-apoptin show typical apoptotic morphology (cell
shrinkage, nuclear condensation). (B) Apoptosis detection in
peripheral blood mononuclear cells treated with recombinant TAT-
GFP (1 M) or recombinant TAT-apoptin (1 M) for the indicated
time, or with 5 g/ml Actinomycin D as a positive control. Some
samples were also treated with IL-2 (5 U) in order to counteract the
spontaneous apoptosis. (C,D) Measurement of apoptosis in Jurkat
caspase-8(–/–) cells (C), Jurkat cells expressing FADD-DN (D), and
control cells treated with TAT-apoptin for the indicated time periods.
To exclude solvent- or TAT-peptide related effects, some control cells
were treated with the recombinant TAT-GFP (1 M) instead of TAT-
apoptin treatment. (E) Apoptosis detection, measured by flow
cytometry, in Jurkat cells either left untreated or treated with the
agonistic anti-CD95 antibody (0.1 g/ml) for 8 hours. Treated Jurkat
caspase-8(–/–) cells and Jurkat cells expressing FADD-DN are also
shown. The percentages of apoptotic cells (mean values of three
independent experiments) are shown. (F) Jurkat and peripheral blood
mononuclear cells (PBLs), isolated by Ficoll-PaqueTM PLUS
gradient (Amersham Biosciences) treated with the recombinant TAT-
Apoptin (1 M) for 12 hours. TAT-apoptin was detected by an anti-
HA antibody, as in A. Cells are counterstained with DAPI.
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as the previously published data (Danen-van Oorschot et al.,
2000). It also shows that although caspase-3 contributes to
the apoptin-triggered death pathway, it can be functionally
replaced by other family members.
The mitochondrial components cytochrome c and AIF
are released upon apoptin-triggered cell death
To further examine the effect of apoptin on mitochondria, we
studied the release of various factors from the mitochondria.
The apoptin-dependent release of cytochrome c from
mitochondria has previously been reported in Saos cells
(Danen-van Oorschot et al., 2000). This same group has also
reported that the apoptin-dependent cytochrome c release,
and the loss of mitochondrial membrane potential, cannot be
blocked by expression of the p35 caspase inhibitor. In
addition to cytochrome c, other signalling molecules such as
AIF and endonuclease G are released from mitchondria in the
presence of various apoptotic signals. Cytochrome c, along
with dATP, Apaf-1 and caspase-9, forms an apoptosome
complex leading to the activation of downstream caspases,
including caspase-3 and caspase-7. By contrast, AIF does not
require apoptosome formation to induce cell death. Thus, in
order to gain further insight into the pathways triggered by
apoptin, we compared the mitochondrial release of both
molecules.
To check the release of cytochrome c from mitochondria
upon apoptin-induced cell death, we separated various
fractions of cells treated with TAT-apoptin and then detected
the protein by western blot. As shown in Fig. 4A, after 36 hours
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Fig. 2. Blocking of CD95/Fas has no effect on apoptin-induced cell
death. (A) Flow cytometry analysis of apoptosis in Jurkat cells, either
grown in control medium or incubated with a human anti-APO-1-
IgG1 (a neutralizing antibody that blocks the interaction of
CD95/APO-1/Fas and the ligand), treated with TAT-apoptin for the
indicated time points. To maintain the blockage, treatment with the
blocking antibody was repeated every 8 hours. To exclude solvent- or
TAT-peptide-related effects, some control cells were treated with
recombinant TAT-GFP (1 M) instead of TAT-apoptin. (B) Control
experiment to assess cell death mediated by CD95. Both control cells
and the Fas-neutralized cells were treated with an anti-Fas (IgM)
antibody, and cell death was measured after 8 hours.
Fig. 3. Mitochondrial membrane potential is lost during apoptin
treatment, and anti-apoptotic Bcl-2 family members block apoptin-
induced death. (A) Mitochondrial membrane potential (m)
determination in Jurkat control cells, caspase-8(–/–) Jurkat cells and
FADD-DN Jurkat cells either left untreated or treated with TAT-
apoptin for the indicated time periods. m was determined by
using a cationic carbocyanine dye, 5,5,6,6-tetrachloro-1,1,3,3-
tetraethylbenzimidazolylcarbocyanine iodide (JC-1), which shows a
decrease in the red fluorescence upon loss of membrane potential.
(B) Apoptosis (hypodiploid nuclei) detection, measured by flow
cytometry, in Jurkat cells and clones stably transfected with either
Bcl-2 or Bcl-XL treated with TAT-apoptin (1 M) for the indicated
time. (C) MCF7, MCF7-Bcl-2 and MCF7-caspase-3 breast cancer
adenocarcinoma cells treated with TAT-Apoptin (1 M) for the
indicated period of time assessed for cell viability by the MTT assay.
To exclude solvent- or TAT-peptide-related effects, some control cells
(A-C) were treated with recombinant TAT-GFP (1 M) instead of
TAT-apoptin.
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of apoptin treatment, significant quantities of cytochrome c are
detected in the cytosol.
In a similar way, we studied the release of AIF from
mitochondria during apoptin-induced cell death. AIF, similarly
to cytochrome c, starts to appear in the cytoplasm around 24-
36 hours after apoptin treatment (Fig. 4A). However, unlike
cytochrome c, AIF goes to the nucleus after it is released from
mitochondria. In the nucleus, AIF causes ‘high-molecular-
weight’ DNA fragmentation and chromatin condensation
(Loeffler and Kroemer, 2000). Using confocal microscopy, we
then investigated whether apoptin caused the nuclear
accumulation of AIF. As shown in Fig. 4B, in the absence of
apoptin, AIF is localized in mitochondria (Fig. 4B, red staining
attributed to Cy3-conjugated mAb). However, when the cells
are treated with TAT-apoptin, after 30 hours most of the AIF
is released from mitochondria and transferred into the nucleus.
Similar results were obtained after transfecting cells with GFP-
apoptin (data not shown). Thus, our data indicate that, apart
from cytochrome c, AIF is also released from mitochondria and
enters the nucleus during apoptin-induced cell death.
Downstream effector caspases are activated during
apoptin-induced cell death
To further investigate the role of the mitochondrial pathway
during apoptin-induced cell death, we studied the activation of
the downstream effector caspases. Once cell death signals
reach the mitochondria, cytochrome c is released to the cytosol
where it triggers the apoptosome pathway, which further
activates downstream caspases, such as caspase-3 and caspase-
7. Thus, we checked the effect of apoptin on the downstream
effector molecule caspase-3. Western blot analysis of Jurkat
cells treated with apoptin shows that the 32 kDa pro-caspase-
3 molecule is cleaved into an active 17 kDa subunit after 48
hours. The cleavage of pro-caspase-3 is inhibited in the
presence of a broad range caspase inhibitor, zVAD-fmk.
However, western blot analysis of pro-caspase-8 cleavage,
which acts proximally at the death receptor pathway, shows no
cleavage in the presence of apoptin (Fig. 5). Thus, these data
further confirm that the intrinsic/mitochondrial death pathway,
and not the death-receptor/extrinsic pathway, is triggered by
apoptin.
Nur77 transmits the apoptin-induced death signal from
the nucleus to the mitochondria
Phosphorylation-dependent nuclear retention of apoptin occurs
only in transformed cells, and it plays an important role in the
toxicity of apoptin. Yet, ultimately, the mitochondrial pathway
becomes activated by apoptin. Nur77 and p53 are the best-
known candidates for nucleo-cytoplasmic apoptotic signalling.
Because it has been reported that apoptin-triggered cell death
is p53 independent (Zhuang et al., 1995a), we tested whether
Nur77, a nuclear orphan receptor and member of the
steroid/thyroid receptor family, plays a role in the apoptin-
induced pathway. Nur77 is capable of transmitting the
apoptotic signal from the nucleus to the mitochondria (Erster
and Moll, 2004; Jeong et al., 2003; Lane and Hupp, 2003; Li
et al., 2000). Furthermore, Nur77 can modulate apoptosis by
activating the transcription of pro- and anti-apoptotic genes
(Rajpal et al., 2003). Inhibition of Nur77 expression in MCF7
cells by specific siRNA (Fig. 6A) strongly protected against
apoptin-induced cell death (Fig. 6B). Furthermore, transfer of
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Fig. 4. Apoptin triggers the release of pro-apoptotic mitochondrial
proteins. (A) Western blot analysis of cytochrome c and AIF in
mitochondrial (Mitoch.), cytosolic (Cytosol) and nuclear fractions of
Jurkat cells treated with apoptin. (B) The precise localization of AIF
in cells, as determined by confocal microscopy. MCF7 cells were
either left untreated or stimulated with TAT-apoptin (1 M). After 36
hours, cells were immunostained with an anti-AIF antibody followed
by the corresponding Cy-3 conjugated secondary antibody (red) and
with an anti-HA-antibody (TAT-apoptin has an incorporated HA-tag)
followed by the detection with a FITC-labelled antibody (green).
Cells were counterstained with DAPI to visualize nuclei.
Fig. 5. Apoptin activates caspase-3 but not caspase-8. Western blot
analysis of cell lysates from Jurkat cells treated with apoptin in the
presence or absence of a caspase inhibitor zVAD-fmk (40 M) for 0,
48 and 60 hours to detect the levels of caspase-3 and caspase-8, and
cleavage. Jurkat cells treated with TAT-GFP are shown as a control.
The molecular sizes of pro-caspase molecules and the active
fragments are indicated.
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Nur77 from the nucleus to the cytoplasm could be observed
within 24-30 hours of the stimulation of MCF7 cells with TAT-
apopin (Fig. 6C). Together, these data indicate that Nur77 is an
integral component, and a downstream signalling molecule,
within the apoptin-triggered cell death pathway.
Discussion
The mechanism of cancer cell-specific apoptosis induction by
apoptin is not known in great detail. Several anti-cancer agents
use components of the death receptor machinery, such as
FADD (Mishima et al., 2003), caspase-8 (Seki et al., 2000),
CD95 (Fulda et al., 1998) and TRAIL receptors (Walczak and
Krammer, 2000; Wen et al., 2000), to kill cancer cells
(reviewed by Wesselborg and Lauber, 2005). Furthermore, it
has been reported previously that apoptin itself partially co-
localizes with FADD in mammalian cells (Guelen et al., 2004).
Using an array of cell lines that are either defective for or
overexpress components of the apoptotic machinery, we have
shown that neither caspase-8 nor FADD, both crucial DISC-
components of pro-apoptotic TNF-R/NGF-R family members,
play a role in apoptin-induced cell death. A number of anti-
cancer drugs upregulate CD95L, which in turn may contribute
to their anti-cancer activity in an autocrine or paracrine manner
(Fulda and Debatin, 2005; Muller et al., 1997). Furthermore,
some previous reports indicate that CD95 can still signal
atypical apoptotic cell death in the absence of caspase-8
(Holler et al., 2000). Thus, by using an anti-CD95 mAb, (APO-
1, IgG1) that inhibits the interaction between CD95 and
CD95L, we have shown that apoptin-induced cell death does
not involve the CD95 receptor triggered by autocrine- or
paracrine-delivered CD95L. Together, these data exclude a role
of the TNF-R/NGF-R family death receptors in apoptin-
induced apoptosis.
The mitochondrial/apoptosome death pathway is ultimately
activated by a number of anti-cancer drugs and stress stimuli
(Creagh and Martin, 2003; Del Bello et al., 2004; Renz et al.,
2001). These stimuli frequently cause the loss of mitochondrial
membrane potential, and the release of cytochrome c, AIF and
other molecules (Antonsson and Martinou, 2000; Hill et al.,
2003; Martinou et al., 2000). The mitochondrial/intrinsic death
pathway is modulated by pro- and anti-apoptotic Bcl-2 family
members (reviewed by Marsden and Strasser, 2003). Apoptin
causes the loss of mitochondrial membrane potential both in
wild-type cells and in clones devoid of functional caspase-8 or
FADD. Apoptin causes the cleavage of caspase-3 and caspase-
7, but not of caspase-8. These data show that apoptin kills
cancer cells by activation of the mitochondrial death pathway
and, furthermore, they show that the caspase-8/Bid-dependent
signal-amplification loop is not important for apoptin-induced
death.
Apoptin cell death signalling triggers the release of
cytochrome c and AIF (which then translocates to the nucleus).
Moreover, the anti-apoptotic Bcl-2 family members Bcl-2 and
Bcl-XL efficiently protect against apoptin-triggered apoptosis,
thus indirectly confirming their involvement in the
mitochondrial death pathway. These data are in contrast to
previous reports by Noteborn and colleagues (Danen-Van
Oorschot et al., 1999; Schoop et al., 2004; Zhuang et al.,
1995b). A possible discrepancy regarding the effect of Bcl-2
family members on apoptin-induced cell death may be
attributed to the different cell lines used in our study.
Nevertheless, we have also observed a strong inhibition of
apoptin-induced cell death in MCF7 breast cancer cell lines
stably transfected with either Bcl-2 (Fig. 3C) or Bcl-XL (data
not shown). Thus, anti-apoptotic Bcl-2 family members seem
to counteract apoptin-triggered cell death in at least some
haematological malignancies and in breast adenocarcinoma
cells. These data corroborate well with the experimental results
reported here that support the involvement of the mitochondrial
death pathway in apoptin-induced cell death.
The cancer-selective toxicity of apoptin, observed by us, and
by a number of other groups (Danen-Van Oorschot et al., 1997;
Guelen et al., 2004; Poon et al., 2005), is intriguing to
Fig. 6. Apoptin-induced cell death depends on Nur77, and involves
its nucleo-cytoplasmic translocation. (A) Detection of Nur77 in
MCF7 cells lipofected with scrambled or Nur77-targeting siRNA;
protein was extracted at 0, 12, 24 and 30 hours post transfection.
Tubulin was included as a loading control. (B) Cell viability of
MCF7 cells treated with TAT-GFP (Control), transfected with Nur77
siRNA, or treated with TAT-apoptin (1 M) either alone or in the
presence of Nur77 siRNA, as determined by MTT assay at the
indicated time points. (C) Confocal microscopy visualization of
Nur77 (green) in MCF7 cells either left untreated or treated with
TAT-apoptin for 30 hours. Mitochondria are stained by Mitotracker®
(red), nuclei with DAPI (blue).
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researchers, as this viral protein targets the molecular basis of
the transformed phenotype. Targeted cancer therapies interfere
with malignant cell growth and division at various points
during the development, growth and spread of cancer. It has
been proposed recently that apoptin kills cancer cells by
interfering with the function of the anaphase-promoting
complex (Teodoro et al., 2004). Interference with the final
stages of mitosis certainly causes cellular stress that would
most likely activate the mitochondrial death pathway.
Furthermore, the toxicity towards (rapidly) dividing cells
would at least in part explain the cancer-selective toxicity of
apoptin. Because apoptin localizes in the cytoplasm of primary
cells but accumulates in the nuclei of transformed cells, it is
tempting to speculate that the selective nuclear localization in
combination with the mitotic interference could largely explain
the cancer-selective effects of apoptin. Recent papers indicate
that nuclear trafficking and tumor-specific phosphorylation of
apoptin at Thr-108 are essential for the induction of apoptosis
(Guelen et al., 2004; Rohn et al., 2002). However, the data
published by Rohn and colleagues indicate that although
phosphorylation of apoptin is required for apoptosis,
abolishing the Thr-108 phosphorylation site of apoptin does
not significantly disrupt its nuclear input in tumor cells (Rohn
et al., 2005). In addition, apoptin can be artificially directed to
the nuclei of primary cells by the attachment of a nuclear
localization signal. In such cases, apoptin still remains non-
toxic to the primary cells (Danen-Van Oorschot et al., 2003;
Guelen et al., 2004; Rohn et al., 2002) (S.M. and M.L.,
unpublished).
We have shown here that, in MCF7 cells, apoptin residing
in the nucleus requires Nur77 for its toxicity. Furthermore, we
have shown that Nur77 translocates to the cytoplasm between
24-30 hours after treatment with TAT-apoptin. Our data
corroborate well with the recent finding (Lee et al., 2005) that
Nur77, in concert with RXR	, translocates from the nucleus
to mitochondria, and that it can directly activate the
mitochondrial death pathway. It is unlikely that the previously
proposed scenario of Nur77-mediated conversion of Bcl-2
from an anti-apoptotic to a pro-apoptotic molecule (Lin et al.,
2004) is among mechanisms contributing to the toxicity of
apoptin, as our experimental data clearly underline the
protective role of both Bcl-2 and Bcl-XL against apoptin-
triggered cell death. Nevertheless, it cannot be excluded that
Nur77 may exert its pro-apototic action by functionally
inhibiting the anti-apoptotic properties of Bcl-2 and Bcl-XL.
Conversely, transcriptional activation of pro-apoptotic genes
that are controlled by Nur77 cannot be ruled out either.
Thus, considering the above observations, and the rather
slow and asynchronous death kinetics triggered by apoptin, we
assume that apoptin employs several different mechanisms to
kill cancer cells. These mechanisms and pathways ultimately
cause cellular stress and converge on the mitochondrial death
pathway.
In conclusion, apoptin induces apoptosis independently of
the death receptor pathway, but it activates the intrinsic/
mitochondrial apoptotic-signalling cascade. At the
mitochondrial level, the apoptin-triggered signal(s) causes the
release of various mitochondrial pro-apoptotic molecules that
either directly propagate the apoptotic process or activate
downstream molecules in the apoptotic signalling pathway.
The nuclear localization of apoptin in transformed cells and the
ultimate activation of the mitochondrial death pathway
suggests that cell death-activating signals must be sent from
the nucleus to mitochondria. At least in our experimental
system, the cytoplasmic translocation of Nur77 is crucial for
the toxicity of apoptin. It remains to be determined whether
Nur77 acts here solely as the signalling molecule, or whether
it concomitantly activates the expression of pro-apoptotic
genes that cooperate in the activation of the apoptotic pathways
in cancer cells (Rajpal et al., 2003).
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